The Advisory Board's Purpose is to:
Provide supportive leadership to develop and implement the College of Chemistry's strategic objectives, to increase our financial strength, fulfill our public mission (education, research and service), and enhance our academic excellence and worldwide reputation.
The Advisory Board's Strategic Objectives include:
- Student Engagement
- Revenue Generation
- Reputation and Brand
Advisory Board Chair
Ronald E. Silva, J.D, , President & CEO , Fillmore Capital Partners, LLC
Ron is the Chairman of the Board of the largest privately held long-term care company in the United States and serves as the Chief Executive Officer and President of Fillmore Capital Partners, LLC. Previously, he served as Executive Vice President of Lowe Enterprises, Inc. Prior to joining Lowe, he developed his early real estate and credit skills as a Vice President for Wells Fargo Bank. He serves as Chairman of the Board of AlixaRx, LLC.
Advisory Board Members
Vik Bajaj, Ph.D., Managing Director, Foresite Capital
Vik is a Managing Director at Foresite, evaluating and pursuing investments at the intersection of technology and life sciences, including personalized and precision healthcare. Prior to joining Foresite Capital, he was the Chief Scientific Officer of GRAIL, a life sciences company working to detect cancer early when it can be cured, and remains on its Scientific Advisory Board. He is also the Co-Founder and former Chief Scientific Officer of Verily (formerly Google Life Sciences) and served as Chair of its Scientific Advisory Board.
Sunney I. Chan, Ph.D. , CalTech, Emeritus George Grant Hoag Professor Biophysical Chemistry
Dr. Chan was an active faculty member at CalTech from 1963 to 2002. He has served on the Academic Sinica as vice-president and was Director of National Research Program of Genomic Medicine, National Science Council, Republic of China among his many prestigious appointments. His research group focuses on the structure and function of membrane proteins.
Nirmal Chatterjee, Ph.D., Retired Vice President Engineering, Air Products and Chemicals; Previous Advisory Board Chair
Nirmal started at Air Products in 1971 after receiving his Ph.D. in chemical engineering from Berkeley with David Lyon. He retired 30 years later as Vice President of Engineering. Air Products core industrial gases business provides atmospheric and process gases and related equipment to manufacturing markets, including refining and petrochemical, metals, electronics, and food and beverage.
Margaret Chu-Moyer, B.S., Executive Director, Amgen Inc.
Margaret leads a team of over a 100 scientists at Amgen, Inc. working on a variety of research projects devoted to creating lifesaving medicines, including projects focused on cancer, heart disease and more. Her teams are involved in the early stages of drug discovery which typically take three to five years work for a treatment to reach patient trials.
Zhiping (Philip) Cui, MBA, Vice President and General Manager of VC Investment Department, Shanghai Fosun Pharmaceutical (Group) Co., Ltd
Philip serves as Vice President of Shanghai Fosun Pharmaceutical (Group) Co., Ltd and has been General Manager of th VC Investment Department since 2016. Previously, he served as General Manager of the International Business Division and Deputy General Manager at Shanghai Fosun Pharmaceutical (Group) Co., Ltd. He serves as Chairman of the Board at Hermed Capital Co., Ltd. and is Director of Handa Pharmaceuticals, LLC.
David Hemker, Ph.D., Chief Technology Officer, Lam Research Corporation
David has spent the past 24 years in the semiconductor equipment industry focusing on advanced technology development. He joined Lam Research Corporation in 1998 as Vice President of New Product Development and is currently the Chief Technology Officer, responsible for long range research and technology development. Prior to joining Lam, he was Vice President of Technology for PMT/Trikon, where he managed research and development, technology, and engineering.
Herbert H. Hooper, Ph.D., Managing General Partner, Ampersand Ventures
Herb joined Ampersand in 2002 with more than fifteen years experience working with Healthcare companies – first as an entrepreneur at Ampersand portfolio company ACLARA Biosciences, and later as an Ampersand Managing Partner. His current and past board seats include ACLARA, Bako, Signature Genomics and Viracor-IBT Laboratories.
Ted Hou, Ph.D., CEO at NEEM Scientific; General Partner, Berkeley Catalyst Fund
Ted is the Founder and CEO of NEEM Scientific, an early stage start-up company with core competence in creating novel nano materials. Efficient devices made from these materials can be used in consumer electronics, energy production, environmental protection, and healthcare. He has worked with large telecom, solar and energy companies in China. With Laura Smoliar and Drew Lanza, he founded the Berkeley Catalyst Fund, an incubator for entrepreneurial startups that will also give back to the College of Chemistry.
Yuan T. Lee, Ph.D., UCB Professor Emeritus, Chemistry; President Emeritus Academia Sinica
Dr. Lee was awarded the Nobel Prize for Chemistry in 1986 and has been honored for his contribution to science by many nations. He holds Honorary Doctorates from 41 universities worldwide. Dr. Lee has been a professor at many institutions including: the University of Chicago; University of California, Berkeley; Honorary Professor at the National Taiwan University; and Distinguished Research Fellow at Academia Sinica. He also served as President of the Academia Sinica from 1994 to 2006.
John H. Markels, Ph.D., President, Latin America, Merck & Co., Inc.
John stepped into the role of President for Merck, Latin America, in January, 2018. Prior to that, he was Senior Vice President, Global Human Health Strategy where he was responsible for developing enterprise strategy for Merck´s biopharmaceutical business. He has been with Merck since 1993.
Gary M. Masada, Ph.D., Retired President and CIO, IT, ERTC Chevron Corporation
Gary joined Chevron as a research chemist in 1972. He held various technical positions at Chevron Research Co. until he transferred to Chevron U.S.A. operations and planning in 1978. Gary ultimately stepped into the role of President and CIO of ChevronTexaco's Information Technology Company in 2003 having previously been president of ChevronTexaco Energy Research and Technology Company.
Alan Mendelson, J.D., Partner, Latham & Watkins, LLP
In Alan's legal practice, he represents emerging and public growth companies, primarily in the life sciences industry. He served as Co-chair of the firm’s Emerging Companies Practice from 2001 to 2013 and currently is Co-chair of the Life Sciences Industry Group. Alan has handled and supervised a variety of major business transactions including venture capital financing, private placements, public offerings, mergers and acquisitions, joint ventures, strategic collaborations and commercial transactions.
R. Andrew Ramelmeier, Ph.D., Senior Vice President, Technical Operations & Manufacturing, Sagamo Therapeutics
Andy joined Sangamo Therapeutics, Inc. in January 2018. Prior to that, he served as Senior Vice President of Biologics Technical Operations at Portola Pharmaceuticals, Inc. since 2014. He has 20 years experience with a strong foundation in the development and manufacturing of biopharmaceuticals, including monoclonal antibodies, vaccines, enzymes and other therapeutic proteins. His technical expertise spans from cell culture and fermentation through purification, formulation and parenteral fill/finish.
Georgieanna Scheuerman, Ph.D., Manager, Applied Research and Catalysis, Chevron Energy Technology Company
Georgieanna oversees a team of researchers who develop technology for Chevron, including refinery and chemical systems that improve the processes of converting crude oil into gasoline and other products that Chevron’s customers use every day. The organization produces both patents and technology.
Charles V. Shank, Ph.D., UCB Emeritus Professor of Chemistry and Physics; Former Director, LBNL
Dr. Shank was Director of LBNL from 1989 to 2004. During his tenure, he oversaw tremendous scientific growth and achievement, expanding programs in astrophysics, computing, genomics, and nanoscience, and doubling the Laboratory’s budget. He joined Berkeley Lab and the University of California, Berkeley faculty in September, 1989. He is professor emeritus in three departments Physics, Chemistry, and Electrical Engineering and Computer Science.
Peter Walther, Ph.D., Senior Vice President, Heterogeneous Catalysis, BASF Corporation
BASF manages a portfolio that includes chemicals, plastics, performance products, agricultural products and fine chemicals to crude oil and natural gas. Through development of new technologies they grow into additional markets. The company strives to conduct business in accordance with the principles of sustainable development
Keith Watson, Ph.D., CFA, Vice President, Core R&D, The Dow Chemical Company
Keith oversees a broad portfolio of corporate research programs and world leading innovation capabilities. He has also held positions as global director of R&D and TS&D for coatings, monomers & plastic additives, specialty chemicals and thermosets.
Ellie Yi-Li Yieh, B.S., Vice President & General Manager, Applied Materials, Inc.
Ellie is Vice President for Advanced Product Technology Development at Applied Materials, Inc. She is responsible for the technical excellence of the company’s state-of-the-art Maydan Technology Center R&D lab. She joined Applied in 1989 as a process engineer in the Chemical Vapor Deposition (CVD) group and has headed several successful product developments over her 20-plus years with the company. She holds over 95 semiconductor engineering patents.